Real-time continuous glucose monitoring (rtCGM) and intermittently scanned CGM (isCGM) have both been shown to improve glycemic outcomes in people with T1D. In this retrospective analysis, we propensity score matched CGM naïve adults with T1D who initiated a rtCGM or an isCGM device. HbA1c and CGM metrics were assessed at 6-12-months.

Among the 143 matched patients/cohort (age 43 ± 14 years; T1D duration 22 ± 14 years; HbA1c 8.4 ± 1.0%) , rtCGM users had a significantly greater change in HbA1c (-0.7 ± 0.1%) compared to isCGM users (-0.4 ± 0.1%) (p=0.01) . There was a significantly greater change in HbA1c for rtCGM compared to isCGM when baseline HbA1c was <8.5% (difference -0.4% [-0.6 to -0.2], p<0.001) , and in MDI users (difference -0.3% [-0.5 to 0.0], p=0.04) . Compared to isCGM users, rtCGM users had significantly greater time in range (58.3 ± 16.1% vs. 54.5 ± 17.1%, p=0.03) , lower time below range (2.1 ± 2.7% vs. 6.1 ± 5.0%, p<0.001) and lower glycemic variability (Table) .

In this real-world analysis of adults with T1D, rtCGM users had a significantly greater reduction in HbA1c at 6-12 months, significantly greater time in range, lower time below range, and lower glycemic variability, compared to a matched cohort of isCGM users.